PHATHOM PHARMACEUTICAL

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

28 Feb 2023 07:00:03 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Provides Regulatory Updates

09 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)

08 Jan 2023 17:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis

03 Jan 2023 15:01:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates

08 Nov 2022 16:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences

03 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement

01 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)

24 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

23 Oct 2022 11:01:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

18 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

26 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

07 Sep 2022 07:15:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates

02 Aug 2022 10:48:42 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

01 Jun 2022 07:15:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis

25 May 2022 07:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022

24 May 2022 11:15:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting

17 May 2022 07:01:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates

10 May 2022 07:00:01 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital

04 May 2022 07:01:00 By Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

03 May 2022 16:40:31 By Nasdaq GlobeNewswire